Rosetta Genomics (ROSG) Gets miRview Mets Approval in NY
Tweet
Share
E-mailGet Alerts ROSG Hot Sheet
Join SI Premium – FREE
Rosetta Genomics, Ltd. (NASDAQ: ROSG), reports the New York State Department of Health has approved miRview mets for testing on patient samples from the state.
New York is the only U.S. state that requires an independent regulatory review process for laboratory developed tests. With this approval, Rosetta Genomics can offer miRview mets in all 50 U.S. states. miRview mets is the Company's proprietary microRNA-based test that identifies the primary origin of many types of tumors of uncertain or unknown origin.
New York is the only U.S. state that requires an independent regulatory review process for laboratory developed tests. With this approval, Rosetta Genomics can offer miRview mets in all 50 U.S. states. miRview mets is the Company's proprietary microRNA-based test that identifies the primary origin of many types of tumors of uncertain or unknown origin.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA clears path for Protagenic's PT00114 anxiety drug IND submission
- Exchange Bank declares Q3 dividend, CEO to retire in 2027
- United Airlines expands Denver pilot training center, phase two planned
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
